Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment
Category: #health  | By Nikita Chaurasia  | Date: 2020-09-16 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment

According to credible sources, the University of Oxford has announced that it will be initiating the Recovery Trial for testing REGN-COV2, an experimental drug developed for the treatment of the COVID-19 virus.

Sources with relevant information stated that a batch of COVID-19 patients in most of NHS (National Health Service) acute hospitals will be randomly subjected to the testing of the novel drug.

For the record, REGN-COV2 has been developed by U.S.-based Regeneron Pharmaceuticals Inc. by combining two human antibodies that neutralize the mutant viruses. The company had previously developed a similar drug against the Ebola virus.

Unlike the initially developed dexamethasone, the new drug specifically targets the COVID-19 virus and has successfully proceeded to its last stage trials in the U.S.

Peter Horby, Chief investigator of the trial as well as a professor of emerging infectious diseases and global health at the Oxford University, was reported stating that although the university has observed positive outcomes of dexamethasone while treating COVID-19 patients, additional new drugs need to be explored to cope with the soaring death rate.

Martin Landray, a professor of medicine & epidemiology and Deputy Chief investigator of the trial expressed his enthusiasm towards the development and stated that the Recovery trial will enable vigorous assessment of REGN-COV2 among hospitalized patients.

However, experts are skeptical over the affordability of the new antibody vaccine, considering the cost of dexamethasone was around £5 to treat a patient with coronavirus.

In other news, British researchers will reportedly test inhaled COVID-19 vaccines developed by Imperial College and Oxford University. As per reliable sources, the trial is aimed at checking whether direct dosage to the respiratory tract can give a better immune response than conventional dosage methods. 

Source credits: https://www.theguardian.com/world/2020/sep/14/new-antibody-drug-added-to-oxford-university-trial-of-covid-19-treatments

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...